📊 UPB Key Takeaways
Is Upstream Bio, Inc. (UPB) a Good Investment?
Upstream Bio is a pre-commercial stage biotech company with minimal revenue ($2.9M) facing unsustainable cash burn of $133.3M annually, providing less than 10 months of runway at current burn rates. While the balance sheet is fortress-like with $101.6M cash and minimal debt, the company will require significant capital raises (causing shareholder dilution) or dramatic revenue acceleration to survive, with no clear path to profitability evident from financial data alone.
Why Buy Upstream Bio, Inc. Stock? UPB Key Strengths
- Strong balance sheet with $339.8M stockholders equity and only $14.0M liabilities
- Excellent liquidity position with 26.15x current ratio and $101.6M cash reserves
- Early revenue traction showing 20.4% year-over-year growth from $2.9M base
UPB Stock Risks: Upstream Bio, Inc. Investment Risks
- Unsustainable cash burn of $133.3M annually against only $2.9M revenue, providing <10 months of runway
- Imminent capital raise requirement will cause significant shareholder dilution
- Massive operating losses (-$160.4M) and -5618.8% operating margin with no profitability timeline disclosed
Key Metrics to Watch
- Monthly cash burn rate and cash runway remaining
- Revenue growth trajectory and path to profitability
- Clinical pipeline advancement and regulatory milestones for product candidates
Upstream Bio, Inc. (UPB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 26.15x current ratio provides a solid financial cushion.
UPB Profit Margin, ROE & Profitability Analysis
UPB vs Healthcare Sector: How Upstream Bio, Inc. Compares
How Upstream Bio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Upstream Bio, Inc. Stock Overvalued? UPB Valuation Analysis 2026
Based on fundamental analysis, Upstream Bio, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Upstream Bio, Inc. Balance Sheet: UPB Debt, Cash & Liquidity
UPB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Upstream Bio, Inc.'s revenue has grown significantly by 20% over the 5-year period, indicating strong business expansion. The most recent EPS of $-5.58 indicates the company is currently unprofitable.
UPB Revenue Growth, EPS Growth & YoY Performance
UPB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $607.0K | -$10.9M | $-0.63 |
| Q2 2025 | $510.0K | -$10.9M | $-0.74 |
| Q1 2025 | $566.0K | -$10.9M | $-0.51 |
| Q3 2024 | $607.0K | -$2.5M | $-2.11 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Upstream Bio, Inc. Dividends, Buybacks & Capital Allocation
UPB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Upstream Bio, Inc. (CIK: 0002022626)
📋 Recent SEC Filings
❓ Frequently Asked Questions about UPB
What is the AI rating for UPB?
Upstream Bio, Inc. (UPB) has an AI rating of SELL with 65% confidence, based on fundamental analysis of SEC EDGAR filings.
What are UPB's key strengths?
Claude: Strong balance sheet with $339.8M stockholders equity and only $14.0M liabilities. Excellent liquidity position with 26.15x current ratio and $101.6M cash reserves.
What are the risks of investing in UPB?
Claude: Unsustainable cash burn of $133.3M annually against only $2.9M revenue, providing <10 months of runway. Imminent capital raise requirement will cause significant shareholder dilution.
What is UPB's revenue and growth?
Upstream Bio, Inc. reported revenue of $2.9M.
Does UPB pay dividends?
Upstream Bio, Inc. does not currently pay dividends.
Where can I find UPB SEC filings?
Official SEC filings for Upstream Bio, Inc. (CIK: 0002022626) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is UPB's EPS?
Upstream Bio, Inc. has a diluted EPS of $-2.66.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is UPB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Upstream Bio, Inc. has a SELL rating with 65% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is UPB stock overvalued or undervalued?
Valuation metrics for UPB: ROE of -42.2% (sector avg: 15%), net margin of -5,026.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy UPB stock in 2026?
Our dual AI analysis gives Upstream Bio, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is UPB's free cash flow?
Upstream Bio, Inc.'s operating cash flow is $-133.3M, with capital expenditures of $165.0K. FCF margin is -4,675.5%.
How does UPB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -5,026.0% (avg: 12%), ROE -42.2% (avg: 15%), current ratio 26.15 (avg: 2).